| Assay ID | Title | Year | Journal | Article |
|---|
| AID476396 | Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as reduction of plasma triglyceride level at 50 mg/kg, po qd for 10 days measured 4 hrs after last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313538 | Decrease in liver cholesterol level in high fat-diet fed syrian golden hamster model of dyslipidemia at 10 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476581 | AUC in cynomolgus monkey at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313535 | Decrease in liver triglyceride level in high fat-diet fed syrian golden hamster model of dyslipidemia at 1 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476590 | Crystalline aqueous solubility at pH 7.9 | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476398 | Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as increase of plasma HDLC level at 10 mg/kg, po qd for 10 days measured 4 hrs after last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476376 | Selectivity ratio of IC50 for human His-tagged PPARgamma (Q203-Y477) to IC50 for human His-tagged PPARalpha (E196-Y468) by fluorescence polarization assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476568 | Half life in Sprague-Dawley rat at 5 mg/kg, ia | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313539 | Decrease in liver cholesterol level in high fat-diet fed syrian golden hamster model of dyslipidemia at 3 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476411 | Half life in BALB/c mouse at 6 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476587 | AUC in cynomolgus monkey at 2 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476414 | AUC (0 to infinity) in BALB/c mouse at 12 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476405 | Antidyslipidemic activity in syrian golden hamster high fat diet model assessed as Reduction of plasma LDLC level at 1 mg/kg, po qd for 21 days measured after 18 hrs fasting and 24 hrs last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476409 | Plasma clearance in BALB/c mouse at 6 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476372 | Selectivity ratio of EC50 for human PPARgamma (176-477) to EC50 for human PPARalpha (167-468) by transactivation assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313546 | Decrease in plasma triglyceride level in high fat-diet fed syrian golden hamster model of dyslipidemia at 10 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476373 | Intrinsic activity at human PPARalpha LBD (167-468) expressed in HEK293 cells coexpressing GAL4-DBD by transactivation assay relative to fenofibric acid | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476412 | Tmax in BALB/c mouse at 12 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476583 | Volume of distribution at steady state in cynomolgus monkey at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476600 | Metabolic stability in human liver microsomes assessed as glutathione conjugate at 30 uM in presence of glutathione | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476608 | Toxicity in monkey assessed as electrocardiographic effects at 20 mg/kg | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476393 | Increase in serum ApoA1 protein level in po dosed human ApoA1 transgenic mouse model administered qd for 10 days measured 4 hrs after last dose | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476609 | Mutagenic activity in Salmonella Typhimurium TA98 up to 5000 ug/plate | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313532 | Decrease in liver triglyceride level in high fat-diet fed syrian golden hamster model of dyslipidemia administered qd through oral gavage measured after 21 days by FPLC analysis | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476417 | Plasma clearance in Sprague-Dawley rat at 5 mg/kg, ia | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476573 | AUC in dog at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476579 | AUC in dog at 2 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476599 | Metabolic stability in rat liver microsomes assessed as glutathione conjugate at 30 uM in presence of glutathione | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476584 | Half life in cynomolgus monkey at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479804 | Induction of hydrase mRNA level in hamster liver at 10 mg/kg, po after 6 hrs relative to fenofibrate | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476592 | Inhibition of human CYP2C8 | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476591 | Inhibition of human CYP1A2 | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476598 | Metabolic stability in mouse liver microsomes assessed as glutathione conjugate at 30 uM in presence of glutathione | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479800 | Half life in Sprague-Dawley rat at 5 mg/kg, iv and 10 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476588 | Oral bioavailability in cynomolgus monkey at 2 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313541 | Decrease in plasma LDL cholesterol level in high fat-diet fed syrian golden hamster model of dyslipidemia administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID479801 | Mean retention time in Sprague-Dawley rat at 5 mg/kg, iv and 10 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID479791 | Agonist activity against human Gal4-fussed PPARalpha by luciferase reporter gene assay relative to finofibrate | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID479803 | Induction of PDK4 mRNA level in hamster liver at 10 mg/kg, po after 6 hrs relative to fenofibrate | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476383 | Selectivity ratio of EC50 for full length human PPARgamma to full length human PPARalpha by luciferase reporter gene assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476394 | Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as reduction of plasma triglyceride level at 100 mg/kg, po qd for 10 days measured 4 hrs after last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476572 | Oral bioavailability in Sprague-Dawley rat at 10 mg/kg | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476594 | Inhibition of human CYP2C19 | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479797 | Drug level in hamster plasma at 10 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476395 | Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as reduction of plasma triglyceride level at 10 mg/kg, po qd for 10 days measured 4 hrs after last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476374 | Binding affinity to human His-tagged PPARalpha LBD (E196-Y468) expressed in Escherichia coli BL21 (DE3) by fluorescence polarization assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313550 | Effect on plasma LDL cholesterol level in high fat-diet fed syrian golden hamster model of dyslipidemia at 1 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis (Rvb = 91.7 +/- 8.1 mg/dl) | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID1313540 | Decrease in liver cholesterol level in high fat-diet fed syrian golden hamster model of dyslipidemia at 1 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476385 | Agonist activity at syrian golden hamster PPARalpha LBD (167-468) expressed in HEK293 cells coexpressing GAL4-DBD by transactivation assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479790 | Agonist activity against human Gal4-fussed PPARalpha in HEK293 cells by luciferase reporter gene assay | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID1313534 | Decrease in liver triglyceride level in high fat-diet fed syrian golden hamster model of dyslipidemia at 3 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID1313551 | Increase in liver cholesterol level in high fat-diet fed syrian golden hamster model of dyslipidemia at 1 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476597 | Agonist activity at human PXR up to 50 uM by transactivation assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476388 | Agonist activity at human RXR by transactivation assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476402 | Antidyslipidemic activity in syrian golden hamster high fat diet model assessed as reduction of plasma triglyceride level at 3 mg/kg, po qd for 21 days measured after 18 hrs fasting and 24 hrs last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313548 | Decrease in plasma triglyceride level in high fat-diet fed syrian golden hamster model of dyslipidemia at 1 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID479793 | Agonist activity against human Gal4-fussed PPARgamma by luciferase reporter gene assay relative to finofibrate | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476413 | Cmax in BALB/c mouse at 12 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476596 | Inhibition of human CYP3A4 | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476582 | Plasma clearance in cynomolgus monkey at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313481 | Agonist activity at rat PPAR-alpha | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476611 | Antiartherosclerosis activity in human po dosed ApoA1 transgenic mouse model assessed as reduction of plasma triglyceride level administered qd for 10 days measured 4 hrs after last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476401 | Antidyslipidemic activity in syrian golden hamster high fat diet model assessed as reduction of plasma triglyceride level at 1 mg/kg, po qd for 21 days measured after 18 hrs fasting and 24 hrs last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313533 | Decrease in liver triglyceride level in high fat-diet fed syrian golden hamster model of dyslipidemia at 10 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID479794 | Antidyslipidemic activity in hamster assessed as decrease in HDL level at 10 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID479806 | Agonist activity at hamster PPARalpha relative to fenofibrate | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476387 | Agonist activity at human LXR by transactivation assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313547 | Decrease in plasma triglyceride level in high fat-diet fed syrian golden hamster model of dyslipidemia at 3 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476571 | AUC in Sprague-Dawley rat at 10 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476585 | Tmax in cynomolgus monkey at 2 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476602 | Cytotoxicity against human hepatocytes | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476408 | AUC (0 to infinity) in BALB/c mouse at 6 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476567 | Volume of distribution at steady state in Sprague-Dawley rat at 5 mg/kg, ia | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479789 | Agonist activity at hamster PPARalpha | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476603 | Inhibition of human ERG at 10 uM by patch clamp assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476570 | Cmax in Sprague-Dawley rat at 10 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476569 | Tmax in Sprague-Dawley rat at 10 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476397 | Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as increase of plasma HDLC level at 100 mg/kg, po qd for 10 days measured 4 hrs after last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476406 | Antidyslipidemic activity in syrian golden hamster high fat diet model assessed as Reduction of plasma LDLC level at 3 mg/kg, po qd for 21 days measured after 18 hrs fasting and 24 hrs last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476589 | Crystalline aqueous solubility at pH 6.5 | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476403 | Antidyslipidemic activity in syrian golden hamster high fat diet model assessed as reduction of plasma triglyceride level at 10 mg/kg, po qd for 21 days measured after 18 hrs fasting and 24 hrs last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476390 | Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as increase in serum ApoA1 protein level at 100 mg/kg, po qd for 10 days measured 4 hrs after last dose | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476607 | Toxicity in monkey assessed as hemodynamic effects at 20 mg/kg | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313544 | Decrease in plasma LDL cholesterol level in high fat-diet fed syrian golden hamster model of dyslipidemia at 3 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID1313480 | Agonist activity at mouse PPAR-alpha | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID479802 | Oral bioavailability in Sprague-Dawley rat at 10 mg/kg | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476407 | Antidyslipidemic activity in syrian golden hamster high fat diet model assessed as Reduction of plasma LDLC level at 10 mg/kg, po qd for 21 days measured after 18 hrs fasting and 24 hrs last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476575 | Volume of distribution at steady state in dog at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476389 | Selectivity ratio of EC50 for human PPARalpha to EC50 for mouse PPARalpha | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476606 | Inhibition of sodium channel at 10 uM at 4 Hz | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476605 | Inhibition of sodium channel at 10 uM at 1 Hz | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476601 | Clastogenic activity in CHO cells | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476384 | Agonist activity at mouse PPARalpha LBD (167-469) expressed in HEK293 cells coexpressing GAL4-DBD by transactivation assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476370 | Agonist activity at human PPARalpha LBD (167-468) expressed in HEK293 cells coexpressing GAL4-DBD by transactivation assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476593 | Inhibition of human CYP2C9 | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476386 | Agonist activity at human PPARdelta by transactivation assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476574 | Plasma clearance in dog at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313479 | Agonist activity at hamster PPAR-alpha | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID476381 | Agonist activity at full length human PPARalpha expressed in HepG2 cells co-transfected with pBL-tk-luciferase by luciferase reporter gene assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476415 | Oral bioavailability in BALB/c mouse at 12 mg/kg | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476410 | Volume of distribution at steady state in BALB/c mouse at 6 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476586 | Cmax in cynomolgus monkey at 2 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476613 | Agonist activity at human PPARdelta by transactivation assay relative to fenofibric acid | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476416 | AUC in Sprague-Dawley rat at 5 mg/kg, ia | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476399 | Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as increase of plasma HDLC level at 50 mg/kg, po qd for 10 days measured 4 hrs after last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476375 | Binding affinity to human His-tagged PPARgamma LBD (Q203-Y477) expressed in Escherichia coli BL21 (DE3) by fluorescence polarization assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479796 | Drug level in hamster liver at 10 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476371 | Agonist activity at human PPARgamma LBD (176-477) expressed in HEK293 cells coexpressing GAL4-DBD by transactivation assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476614 | Agonist activity at human LXR by transactivation assay relative to fenofibric acid | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479792 | Agonist activity against human Gal4-fussed PPARgamma in HEK293 cells by luciferase reporter gene assay | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476576 | Half life in dog at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476382 | Agonist activity at full length human PPARgamma expressed in HepG2 cells co-transfected with pBL-tk-luciferase by luciferase reporter gene assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479795 | Antidyslipidemic activity in hamster assessed as decrease in triglyceride level at 10 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476392 | Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as increase in serum ApoA1 protein level at 50 mg/kg, po qd for 10 days measured 4 hrs after last dose | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479798 | Volume of distribution at steady state Sprague-Dawley rat at 5 mg/kg, iv and 10 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476615 | Agonist activity at human RXR by transactivation assay relative to fenofibric acid | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476612 | Antiartherosclerosis activity in human ApoA1 transgenic mouse mode assessed as increase of plasma HDLC level in po dosed l administered qd for 10 days measured 4 hrs after last dose by FPLC method | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID479805 | Ratio of EC50 for human PPARgamma to EC50 for human PPARalpha | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476578 | Cmax in dog at 2 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476580 | Oral bioavailability in dog at 2 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476604 | Inhibition of human ERG at 30 uM by patch clamp assay | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476391 | Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as increase in serum ApoA1 protein level at 10 mg/kg, po qd for 10 days measured 4 hrs after last dose | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476595 | Inhibition of human CYP2D6 | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID476577 | Tmax in dog at 2 mg/kg, po | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1313543 | Decrease in plasma LDL cholesterol level in high fat-diet fed syrian golden hamster model of dyslipidemia at 10 mg/kg administered qd through oral gavage measured after 21 days by FPLC analysis relative to control | 2016 | ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
| Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist. |
| AID479799 | Clearance in Sprague-Dawley rat at 5 mg/kg, iv and 10 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. |
| AID476610 | Mutagenic activity in Salmonella Typhimurium TA100 up to 5000 ug/plate | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
| Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1798931 | Cell-Based Transcription Assay from Article 10.1124/jpet.108.143271: \\Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol | 2008 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 327, Issue:3
| Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. |
| AID1798929 | PPAR alpha Fluorescence Polarization Assay (IC50) and Cell-Based Transcription Assay (EC50) from Article 10.1124/jpet.108.143271: \\Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high- | 2008 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 327, Issue:3
| Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. |
| AID1798930 | PPAR gamma Fluorescence Polarization Assay (IC50) and Cell-Based Transcription Assay (EC50) from Article 10.1124/jpet.108.143271: \\Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high- | 2008 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 327, Issue:3
| Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |